462 related articles for article (PubMed ID: 23467636)
1. Inequities in access to biologic and synthetic DMARDs across 46 European countries.
Putrik P; Ramiro S; Kvien TK; Sokka T; Pavlova M; Uhlig T; Boonen A;
Ann Rheum Dis; 2014 Jan; 73(1):198-206. PubMed ID: 23467636
[TBL] [Abstract][Full Text] [Related]
2. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
Putrik P; Ramiro S; Kvien TK; Sokka T; Uhlig T; Boonen A;
Ann Rheum Dis; 2014 Nov; 73(11):2010-21. PubMed ID: 23940213
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
Gabay C; Riek M; Scherer A; Finckh A;
Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
[TBL] [Abstract][Full Text] [Related]
4. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
[TBL] [Abstract][Full Text] [Related]
5. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.
Bergstra SA; Branco JC; Vega-Morales D; Salomon-Escoto K; Govind N; Allaart CF; Landewé RBM
Ann Rheum Dis; 2018 Oct; 77(10):1413-1420. PubMed ID: 29980576
[TBL] [Abstract][Full Text] [Related]
6. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
[TBL] [Abstract][Full Text] [Related]
7. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
[TBL] [Abstract][Full Text] [Related]
8. Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.
Nikiphorou E; van der Heijde D; Norton S; Landewé RB; Molto A; Dougados M; Van den Bosch FE; Ramiro S
Ann Rheum Dis; 2018 Mar; 77(3):405-411. PubMed ID: 29222349
[TBL] [Abstract][Full Text] [Related]
9. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study.
Lampropoulos CE; Orfanos P; Bournia VK; Karatsourakis T; Mavragani C; Pikazis D; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2015; 33(2):216-24. PubMed ID: 25664400
[TBL] [Abstract][Full Text] [Related]
10. Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study.
Putrik P; Ramiro S; Keszei AP; Hmamouchi I; Dougados M; Uhlig T; Kvien TK; Boonen A
Ann Rheum Dis; 2016 Mar; 75(3):540-6. PubMed ID: 25630346
[TBL] [Abstract][Full Text] [Related]
11. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
[TBL] [Abstract][Full Text] [Related]
13. Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.
Koike T
J Orthop Sci; 2015 Nov; 20(6):951-7. PubMed ID: 26404390
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
[TBL] [Abstract][Full Text] [Related]
16. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
17. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries.
Orlewska E; Ancuta I; Anic B; Codrenau C; Damjanov N; Djukic P; Ionescu R; Marinchev L; Nasonov EL; Peets T; Praprotnik S; Rashkov R; Skoupa J; Tlustochowicz W; Tlustochowicz M; Tomsic M; Veldi T; Vojinovic J; Wiland P
Med Sci Monit; 2011 Apr; 17(4):SR1-13. PubMed ID: 21455121
[TBL] [Abstract][Full Text] [Related]
18. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewé RBM
Ann Rheum Dis; 2017 Jun; 76(6):1101-1136. PubMed ID: 28298374
[TBL] [Abstract][Full Text] [Related]
19. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
20. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies.
Jönsson B; Kobelt G; Smolen J
Eur J Health Econ; 2008 Jan; 8 Suppl 2():S61-86. PubMed ID: 18097697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
